Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc.

康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6185)

POLL RESULTS OF THE 2018 ANNUAL GENERAL MEETING AND CHANGE OF MEMBERS OF THE BOARD OF DIRECTORS AND ITS AUDIT COMMITTEE

POLL RESULTS OF THE ANNUAL GENERAL MEETING

The Board hereby announces that the poll results in respect of the resolutions proposed at the AGM held on Friday, June 28, 2019. All resolutions were duly passed.

CHANGE OF MEMBERS OF THE BOARD AND ITS AUDIT COMMITTEE

The Board hereby announces that Mr. Zhi XIAO has been appointed as a non-executive Director and a member of the Audit Committee. Dr. Zheng YIN ceased to be a non-executive Director and a member of the Audit Committee upon conclusion of the AGM.

Reference is made to the circular (the "Circular") of CanSino Biologics Inc. (the "Company") incorporating, amongst others, the notice (the "Notice") of 2018 annual general meeting of the Company (the "AGM") dated May 13, 2019. Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as those defined in the Circular.

POLL RESULTS OF THE AGM

The Board is pleased to announce that the AGM was held at Room Pacific B, Pan Pacific Hotel Tianjin, No.1 Zhangzizhong Road, Hongqiao District, Tianjin, China on Friday, June 28, 2019 at 9:00 a.m.

As at the date of the AGM, the issued share capital of the Company and the total number of shares entitling the holders to attend and vote on the resolutions proposed at the AGM was 222,649,899 Shares, comprising 73,254,799 Domestic Shares, 16,724,200 Unlisted Foreign Shares and 132,670,900 H Shares.

Shareholders (including proxies) representing 194,696,554 Shares (including 70,103,376 Domestic Shares, 16,724,200 Unlisted Foreign Shares and 107,868,978 H Shares) or approximately 87.45% of the total issued share capital of the Company attended the AGM.

To the best knowledge, information and belief of the Company: (1) there were no Shares entitling the holder to attend and abstain from voting in favour of the resolutions proposed at the AGM as set out in rule 13.40 of the Listing Rules; (2) no Shareholder was required under the Listing Rules to abstain from voting on the resolutions proposed at the AGM; and (3) no party has stated any intention in the Circular to vote against or to abstain from voting on any of the resolutions proposed at the AGM.

The poll results in respect of the AGM were as follows:

ORDINARY RESOLUTIONS		Number of Votes $(\%)^{(1)}$			Passed by
		For	Against	Abstain	Shareholders
1.	To consider and approve the proposed appointment of Mr. Zhi XIAO as non-executive director of the Company.	194,696,554 100%	0 0%	0 0%	Yes
2.	To consider and approve the re-appointment of PricewaterhouseCoopers Zhong Tian LLP, Beijing Branch (普華永道中天會計師事務所 (特殊普通合夥) 北京分所) and PricewaterhouseCoopers as the domestic auditor and overseas auditor for 2019 respectively and authorize the Board to fix their remunerations.	194,696,554 100%	0	0 0%	Yes
3.	To consider and approve the new credit applications in an aggregate amount of up to RMB500 million or the equivalent in other currencies.	194,696,554 100%	0 0%	0 0%	Yes
SPECIAL RESOLUTION		Number of Votes (%)(1)			Passed by
		For	Against	Abstain	Shareholders
4.	To grant a general mandate to the Board to issue, allot and deal with additional domestic shares, unlisted foreign shares and H shares not exceeding 20% of each of the total number of the domestic shares, unlisted foreign shares and H shares respectively in issue, and to authorize the Board to make amendments to the articles of association of the Company as it thinks fit so as to reflect the new share capital structure upon the issue or allotment of additional shares pursuant to such mandate.	168,111,554 87.96%	23,017,800 12.04%	3,567,200	Yes

Note 1: For the purpose of calculating the result of the resolutions, only the votes "For" and "Against" shall be regarded as voting rights. The votes "Abstain" shall not be regarded as voting rights.

As more than one half of the votes were cast in favour of the ordinary resolutions numbered 1 to 3 above, these resolutions were duly passed.

As more than two-thirds of the vote was cast in favour of the special resolution numbered 4 above, the resolution was duly passed.

The H share registrar of the Company, Computershare Hong Kong Investor Services Limited, acted as the scrutineer for the vote-taking at the AGM. Two representatives of the Shareholders, a lawyer of Tian Yuan Law Firm, and a Supervisor of the Company participated in the scrutiny of the poll results.

CHANGE OF MEMBERS OF THE BOARD AND ITS AUDIT COMMITTEE

At the AGM, Mr. Zhi XIAO ("Mr. Xiao") was appointed as a non-executive Director of the first session of the Board and a member of the audit committee of the Board (the "Audit Committee"). The appointment of Mr. Xiao shall come into effect immediately after the conclusion of the AGM and until the expiry of the term of the first session of the Board. For the details of Mr. Xiao's biography and the determination of his remuneration, please refer to the announcement of the Company dated May 10, 2019 and the Circular. As at the date of this announcement, there has been no change in such information.

Dr. Zheng YIN ceased to be a non-executive Director and a member of the Audit Committee upon conclusion of the AGM.

By order of the Board CanSino Biologics Inc. Xuefeng YU Chairman

Hong Kong, June 28, 2019

As at the date of this announcement, the Board of Directors comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU and Dr. Dongxu QIU as executive Directors, Mr. Qiang XU, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive Directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Dr. Luis BARRETO and Dr. Pierre Armand MORGON as independent non-executive Directors.